CY2023016I2 - Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του - Google Patents

Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Info

Publication number
CY2023016I2
CY2023016I2 CY2023016C CY2023016C CY2023016I2 CY 2023016 I2 CY2023016 I2 CY 2023016I2 CY 2023016 C CY2023016 C CY 2023016C CY 2023016 C CY2023016 C CY 2023016C CY 2023016 I2 CY2023016 I2 CY 2023016I2
Authority
CY
Cyprus
Prior art keywords
polypeptide
production
modified factor
factor
modified
Prior art date
Application number
CY2023016C
Other languages
English (en)
Other versions
CY2023016I1 (el
Original Assignee
Uniqure Biopharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2023016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it
Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it
Application filed by Uniqure Biopharma B.V. filed Critical Uniqure Biopharma B.V.
Publication of CY2023016I2 publication Critical patent/CY2023016I2/el
Publication of CY2023016I1 publication Critical patent/CY2023016I1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY2023016C 2008-09-15 2023-07-27 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του CY2023016I1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITBO2008A000564A IT1394177B1 (it) 2008-09-15 2008-09-15 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it) 2009-05-06 2009-05-06 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
EP09748260.8A EP2337849B1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production
EP17175191.0A EP3252157A1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production
PCT/EP2009/061935 WO2010029178A1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production

Publications (2)

Publication Number Publication Date
CY2023016I2 true CY2023016I2 (el) 2024-02-16
CY2023016I1 CY2023016I1 (el) 2024-02-16

Family

ID=41397565

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20231100138T CY1125885T1 (el) 2008-09-15 2023-03-14 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του
CY2023016C CY2023016I1 (el) 2008-09-15 2023-07-27 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20231100138T CY1125885T1 (el) 2008-09-15 2023-03-14 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Country Status (17)

Country Link
US (11) US9249405B2 (el)
EP (5) EP3581650B1 (el)
CA (1) CA2737094C (el)
CY (2) CY1125885T1 (el)
DK (2) DK2337849T3 (el)
ES (2) ES2940323T3 (el)
FI (2) FI3581650T3 (el)
FR (1) FR23C1028I1 (el)
HK (1) HK1244507A1 (el)
HR (2) HRP20230259T1 (el)
HU (2) HUE061345T2 (el)
LT (2) LT3581650T (el)
PL (2) PL3581650T3 (el)
PT (1) PT3581650T (el)
SI (1) SI3581650T1 (el)
TR (1) TR201813067T4 (el)
WO (1) WO2010029178A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230259T1 (hr) 2008-09-15 2023-04-28 Uniqure Biopharma B.V. Mutant polipeptida faktora ix, njegove primjene i postupak za njegovu proizvodnju
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
JP6363600B2 (ja) 2012-07-25 2018-07-25 カタリスト・バイオサイエンシーズ・インコーポレイテッドＣａｔａｌｙｓｔ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 修飾第ｘ因子ポリペプチドおよびその使用
HUE063051T2 (hu) 2013-02-15 2023-12-28 Bioverativ Therapeutics Inc Optimalizált VIII. faktor gén
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EP4378487A2 (en) 2015-06-23 2024-06-05 The Children's Hospital of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
BR112018015659A2 (pt) 2016-02-01 2018-12-26 Bioverativ Therapeutics Inc genes otimizados do fator viii
BR112019001532A2 (pt) 2016-07-26 2019-09-10 Biomarin Pharm Inc proteínas de capsídeo de vírus adenoassociado inovadoras
CN106497949A (zh) * 2016-10-14 2017-03-15 上海交通大学医学院附属瑞金医院 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
CA3064730A1 (en) 2017-05-22 2018-11-29 Baxalta Incorporated Viral vectors encoding recombinant fix variants with increased expression for gene therapy of hemophilia b
EP3652326A1 (en) 2017-07-10 2020-05-20 uniQure IP B.V. Means and methods for aav gene therapy in humans
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
PE20210112A1 (es) 2018-05-09 2021-01-19 Biomarin Pharm Inc Metodos de tratamiento de fenilcetonuria
AR117427A1 (es) 2018-05-14 2021-08-04 Biomarin Pharm Inc Expresión estable de vectores de aav en sujetos jóvenes
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
KR20210049129A (ko) * 2018-08-20 2021-05-04 유씨엘 비즈니스 리미티드 인자 ix를 코딩하는 뉴클레오타이드
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
WO2023275024A1 (en) * 2021-07-01 2023-01-05 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US6227618B1 (en) 1996-02-23 2001-05-08 Schukra Usa, Inc. Cable attachment for a lumbar support
EP0917566B1 (de) 1996-06-11 2004-09-22 Roche Diagnostics GmbH Rekombinante blutgerinnungsproteasen
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
DE69841459D1 (en) 1997-02-14 2010-03-11 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
WO2001070763A1 (en) 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
PL369065A1 (en) 2001-09-04 2005-04-18 Merck Patent Gmbh Modified factor ix
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US20060292117A1 (en) * 2002-04-17 2006-12-28 Loiler Scott A Improved rAAv vectors
EP2444809A3 (en) 2002-10-02 2013-07-24 Catalyst Biosciences, Inc. Methods of generating and screening for proteases with altered specificity
EP2281877A3 (en) * 2003-05-21 2011-06-01 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
DE602005021509D1 (de) 2004-08-17 2010-07-08 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
DE502004008275D1 (de) 2004-08-19 2008-11-27 Gerd Baer Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en) 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
ES2381796T3 (es) * 2004-09-22 2012-05-31 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
NZ595193A (en) 2005-10-21 2013-09-27 Catalyst Biosciences Inc Modified Proteases That Inhibit Complement Activation
WO2007059473A2 (en) * 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
PT1969127E (pt) 2005-12-21 2014-09-23 Univ North Carolina Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes
WO2007089632A2 (en) 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
WO2007101681A1 (en) * 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
US20080038224A1 (en) 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
EP2007795B1 (en) * 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
WO2007118245A2 (en) * 2006-04-07 2007-10-18 The Board Of Regents Of The University Of Texas System Methods and compositions related to adenoassociated virus-phage particles
MX2008014685A (es) 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
US20070280906A1 (en) * 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
ES2535877T3 (es) 2006-06-19 2015-05-18 Asklepios Biopharmaceutical, Inc. Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
US20080214462A1 (en) * 2007-02-01 2008-09-04 Baxter International Inc. FIX-Mutant Proteins for Hemophilia B Treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
US20100137211A1 (en) 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
BRPI0705943A2 (pt) 2007-04-19 2008-12-09 Nautilus Biotech formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
EP2209487A4 (en) 2007-10-15 2012-06-20 Univ North Carolina VARIANTS OF HUMAN FACTOR IX WITH EXTENDED HALF-TIME
RU2010146387A (ru) * 2008-04-16 2012-05-27 БАЙЕР ХЕЛСКЕР ЛЛСи (US) Модифицированные полипептиды фактора ix и их применение
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
JP5665733B2 (ja) 2008-04-21 2015-02-04 ノボ ノルディスク ヘルス ケア アーゲー 高度にグリコシル化されたヒト凝固第ｉｘ因子
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
HRP20230259T1 (hr) 2008-09-15 2023-04-28 Uniqure Biopharma B.V. Mutant polipeptida faktora ix, njegove primjene i postupak za njegovu proizvodnju
RU2563231C2 (ru) 2009-06-25 2015-09-20 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Химерные молекулы фактора vii
MX2012001346A (es) 2009-07-31 2012-02-17 Bayer Healthcare Llc Polipeptidos del factor ix modificados y usos de los mismos.
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US10398787B2 (en) 2012-10-26 2019-09-03 Vrije Universiteit Brussel Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
WO2016146757A1 (en) 2015-03-17 2016-09-22 Vrije Universiteit Brussel Optimized liver-specific expression systems for fviii and fix
EP4378487A2 (en) 2015-06-23 2024-06-05 The Children's Hospital of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法

Also Published As

Publication number Publication date
WO2010029178A1 (en) 2010-03-18
EP4219547A3 (en) 2023-10-18
PT3581650T (pt) 2023-03-08
US20200190498A1 (en) 2020-06-18
EP3581650A2 (en) 2019-12-18
US10465180B2 (en) 2019-11-05
LT3581650T (lt) 2023-05-10
FI3581650T3 (fi) 2023-03-23
CA2737094C (en) 2018-02-20
CY1125885T1 (el) 2024-02-16
EP4219547A2 (en) 2023-08-02
US20210214704A1 (en) 2021-07-15
US9982248B2 (en) 2018-05-29
HUE061345T2 (hu) 2023-06-28
EP3581650A3 (en) 2020-03-25
US20180258413A1 (en) 2018-09-13
TR201813067T4 (tr) 2018-09-21
US20220002702A1 (en) 2022-01-06
US9249405B2 (en) 2016-02-02
US20160122740A1 (en) 2016-05-05
DK3581650T3 (da) 2023-03-13
CA2737094A1 (en) 2010-03-18
US20220090042A1 (en) 2022-03-24
LTPA2023521I1 (el) 2023-08-25
PL2337849T3 (pl) 2018-11-30
EP2337849A1 (en) 2011-06-29
DK2337849T3 (en) 2018-10-01
PL3581650T3 (pl) 2023-05-22
US20170355973A1 (en) 2017-12-14
EP2337849B1 (en) 2018-06-13
SI3581650T1 (sl) 2023-06-30
FIC20230026I1 (fi) 2023-07-25
HRP20230259T1 (hr) 2023-04-28
FR23C1028I1 (fr) 2023-10-06
US20200231958A1 (en) 2020-07-23
HK1244507A1 (zh) 2018-08-10
HRP20181442T1 (hr) 2018-12-14
ES2940323T3 (es) 2023-05-05
US20200199564A1 (en) 2020-06-25
EP3581650B1 (en) 2022-12-28
EP4032979A1 (en) 2022-07-27
EP4032979B1 (en) 2024-05-01
US20110244550A1 (en) 2011-10-06
ES2687038T3 (es) 2018-10-23
CY2023016I1 (el) 2024-02-16
EP4032979C0 (en) 2024-05-01
CA2737094F (en) 2010-03-18
EP3252157A1 (en) 2017-12-06
HUS2300024I1 (hu) 2023-08-28
US20210238573A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
CY2023016I1 (el) Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του
BRPI0906752A2 (pt) promotor aprimorado e método para a produção de l-lisina usando o mesmo
NL2001649A1 (nl) Non-bolt joint structure and method for producing non-bolt joint structure.
BRPI0913227A2 (pt) método, e objeto
DK2252633T3 (da) Anti-TrkA antistoffer og derivater deraf
BRPI0916615A2 (pt) Construtos e métodos para a produção e secreção de polipeptídeos
BRPI0822112A8 (pt) sensor, método para detecção e método para produzir um sensor
FI20061090A (fi) Kunnonvalvontamenetelmä
DE602006016683D1 (de) Tonerherstellungsverfahren
BRPI0813858A2 (pt) Método para produzir peptídeo
BRPI0923299A8 (pt) método para a produção de minérios sinterizado
FI20075584A0 (fi) Menetelmä nosturin ohjaamiseksi
BRPI0718068A2 (pt) Material compósito, e, método
EP2189476A4 (en) NOVEL POLYPEPTIDE AND MANUFACTURING METHOD THEREFOR
BRPI0910880A2 (pt) mangueira compósita, e, método para produzir uma mangueira compósita.
BRPI0815419A2 (pt) Método de produção
IT1394172B1 (it) Metodo prognostico
FI20070554A0 (fi) Uusi valmistusmenetelmä
DK2062053T3 (da) Forbedret immunoanalysefremgangsmåde
FI20060460A (fi) Menetelmä terästuotannon yhteydessä
JP2010285712A5 (ja) ゴム物品補強用スチールコードおよびその製造方法
IT1394177B1 (it) Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
FI20095850A0 (fi) Rakennelma ja menetelmä rakennelman valmistamiseksi, sekä rakennelman käyttö
FI20061110A0 (fi) Kunnonvalvontamenetelmä
IT1395980B1 (it) Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione